Contributions
Abstract: PS1172
Type: Poster Presentation
Presentation during EHA23: On Saturday, June 16, 2018 from 17:30 - 19:00
Location: Poster area
Background
The ECHELON-1 trial demonstrated improved outcomes for patients with advanced Hodgkin lymphoma (HL) who received frontline A+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) vs ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), with 2-year modified progression-free survival (mPFS) rates of 82% and 77%, respectively.
Aims
In this post-hoc analysis, we examine the mPFS outcomes and clinical characteristics by Cycle 2 positron-emission tomography (PET2) status, per independent review facility (IRF).
Methods
Patients were randomized 1:1 to A+AVD or ABVD on Days 1 and 15 for up to six 28-day cycles. PET scans were conducted at the end of Cycle 2 and end of treatment. PET2 results guided an optional switch to alternative therapy at the treating physician’s discretion for patients with a Deauville score of 5. A switch to alternative therapy was not considered an event. The primary endpoint, mPFS, was defined as time to progression, death, or absence of a complete response with subsequent anticancer therapy, per IRF.
Results
PET2 negativity rates (Deauville ≤3) were 89% (588/664 patients) in the A+AVD arm and 86% (577/670) with ABVD. Baseline characteristics were well-balanced across arms, with no significant differences in PET2– vs PET2+ patients in either arm. PET2 positivity rates (Deauville ≥4) were 7% (47/644) in the A+AVD arm and 9% (58/670) with ABVD; in total, 5 patients with a Deauville score of 5 switched to alternative frontline therapy. Subgroup analyses showed a favorable treatment effect for both subgroups in favor of A+AVD (Table), with 2-year mPFS (PET2– vs PET2+) of 85.2 vs 57.5% in the A+AVD arm, and 80.9 vs 42.0% in the ABVD arm. In both arms, outcomes for PET2+ patients were poor compared with PET– patients, consistent with findings from other studies.
Conclusion
Overall, ECHELON-1 demonstrated a treatment effect in favor of A+AVD over ABVD. This post-hoc analysis showed a similar treatment effect on mPFS consistently in favor of A+AVD regardless of PET2 status.
Session topic: 17. Hodgkin lymphoma – Clinical
Keyword(s): CD30, Clinical Trial, Hodgkin's Lymphoma
Abstract: PS1172
Type: Poster Presentation
Presentation during EHA23: On Saturday, June 16, 2018 from 17:30 - 19:00
Location: Poster area
Background
The ECHELON-1 trial demonstrated improved outcomes for patients with advanced Hodgkin lymphoma (HL) who received frontline A+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) vs ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), with 2-year modified progression-free survival (mPFS) rates of 82% and 77%, respectively.
Aims
In this post-hoc analysis, we examine the mPFS outcomes and clinical characteristics by Cycle 2 positron-emission tomography (PET2) status, per independent review facility (IRF).
Methods
Patients were randomized 1:1 to A+AVD or ABVD on Days 1 and 15 for up to six 28-day cycles. PET scans were conducted at the end of Cycle 2 and end of treatment. PET2 results guided an optional switch to alternative therapy at the treating physician’s discretion for patients with a Deauville score of 5. A switch to alternative therapy was not considered an event. The primary endpoint, mPFS, was defined as time to progression, death, or absence of a complete response with subsequent anticancer therapy, per IRF.
Results
PET2 negativity rates (Deauville ≤3) were 89% (588/664 patients) in the A+AVD arm and 86% (577/670) with ABVD. Baseline characteristics were well-balanced across arms, with no significant differences in PET2– vs PET2+ patients in either arm. PET2 positivity rates (Deauville ≥4) were 7% (47/644) in the A+AVD arm and 9% (58/670) with ABVD; in total, 5 patients with a Deauville score of 5 switched to alternative frontline therapy. Subgroup analyses showed a favorable treatment effect for both subgroups in favor of A+AVD (Table), with 2-year mPFS (PET2– vs PET2+) of 85.2 vs 57.5% in the A+AVD arm, and 80.9 vs 42.0% in the ABVD arm. In both arms, outcomes for PET2+ patients were poor compared with PET– patients, consistent with findings from other studies.
Conclusion
Overall, ECHELON-1 demonstrated a treatment effect in favor of A+AVD over ABVD. This post-hoc analysis showed a similar treatment effect on mPFS consistently in favor of A+AVD regardless of PET2 status.
Session topic: 17. Hodgkin lymphoma – Clinical
Keyword(s): CD30, Clinical Trial, Hodgkin's Lymphoma